BeOne Medicines (BEIGF) Current Deferred Revenue (2015 - 2023)

BeOne Medicines (BEIGF) has 8 years of Current Deferred Revenue data on file, last reported at $159.0 million in Q2 2023.

• Current Deferred Revenue for Q2 2023 came in at $159.0 million, down 2.67% year-over-year; the trailing twelve-month figure through Jun 2023 was $159.0 million (down 2.67% YoY), and the FY2022 annual result was $213.9 million, down 28.71% from the prior year.
• Current Deferred Revenue slipped to $159.0 million in Q2 2023 per BEIGF's latest filing, from $185.5 million in the prior quarter.
• Over five years, Current Deferred Revenue peaked at $300.0 million in Q4 2021 and troughed at $17.5 million in Q1 2019.
• A 4-year average of $141.4 million and a median of $159.0 million in 2023 frame the typical range for Current Deferred Revenue.
• On a YoY basis, Current Deferred Revenue climbed as much as 156.89% in 2022 and fell as far as 28.71% in 2022.
• A 4-year view of Current Deferred Revenue shows it stood at $17.5 million in 2019, then surged by 1613.89% to $300.0 million in 2021, then slipped by 28.71% to $213.9 million in 2022, then retreated by 25.64% to $159.0 million in 2023.
• Business Quant data shows BEIGF's Current Deferred Revenue at $159.0 million in Q2 2023, $185.5 million in Q1 2023, and $213.9 million in Q4 2022.